en O20: NK Cells as Surrogate Marker for Predicting Treatment Efficacy in Chronic Inflammatory Demyelinating Polyneuropathy تحقیقات پایه در علوم اعصاب Basic research in Neuroscience مروری Review --- Open Access, CC-BY-NC <div style="text-align: center;"><span style="text-align: center; color: rgb(0, 0, 0); text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: Tahoma; font-size: 12px; font-style: normal; font-weight: 400; word-spacing: 0px; float: none; display: inline !important; white-space: normal; orphans: 2; widows: 2; background-color: rgb(251, 250, 249); font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">لطفاً به چکیده انگلیسی مراجعه شود.</span></div> <p style="text-align: justify;">Natural Killer (NK) cells are part of our innate immune system with regulatory and effector functions. Different studies suggest that treatment with intravenous immunoglobulins (IVIg) has an immunomodulatory effect on NK cells. IVIg is a first-line treatment for various autoimmune diseases in particular in chronic inflammatory demyelinating polyneuropathy (CIDP). The lack of predictive markers for IVIg responsiveness in CIDP avoids the early preservation of non-responding patients. Using semi-quantitative PCR and flow cytometry in the peripheral blood of patients with CIDP, we analysed the effects of IVIg on the NK cells and correlated changes with the IVIg reponsiveness. IVIg administrations induced a reduction in the expression of several typical NK cell genes. Flow cytometry data revealed that IVIg reduced the cytotoxic CD56dim NK cell population, while regulatory CD56bright NK cells remained almost unaffected or were even increased. Interestingly, the observed effects on NK cells almost exclusively occurred in IVIg responding CIDP patients. Correlation between changes in the NK cell population and treatment efficiency suggests a crucial role for NK cells in the immunomodulatory mechanism of IVIg. Further studies will investigate whether differences in the NK cell status of CIDP patients represent a reliable surrogate marker predicting the outcome of IVIg therapy.</p> NK Cells, Chronic Inflammatory, Demyelinating Polyneuropathy 20 20 http://shefayekhatam.ir/browse.php?a_code=A-10-24-1090&slc_lang=en&sid=1 Anne Kathrin Mausberg Anne Kathrin Mausberg anne-kathrin.mausberg@uk-essen.de 100319475328460015406 100319475328460015406 Yes University Hospital Essen, Neurology, Essen, Germany University Hospital Essen, Neurology, Essen, Germany M. K. Heininger M. K. Heininger 100319475328460015407 100319475328460015407 No Heinrich-Heine-University, Neurology, Duesseldorf, Germany Heinrich-Heine-University, Neurology, Duesseldorf, Germany G. Meyer Zu Horste G. Meyer Zu Horste 100319475328460015408 100319475328460015408 No University of Muenster, Neurology, Muenster, Germany University of Muenster, Neurology, Muenster, Germany S Cordes S Cordes 100319475328460015409 100319475328460015409 No Charité Berlin, Department of Hematology, Oncology & Tumor Immunology, Berlin/Germany Charité Berlin, Department of Hematology, Oncology & Tumor Immunology, Berlin/Germany C Kleinschnitz C Kleinschnitz 100319475328460015410 100319475328460015410 No University Hospital Essen, Neurology, Essen, Germany University Hospital Essen, Neurology, Essen, Germany B. C Kieseier B. C Kieseier 100319475328460015411 100319475328460015411 No Heinrich-Heine-University, Neurology, Duesseldorf, Germany Heinrich-Heine-University, Neurology, Duesseldorf, Germany M Stettner M Stettner 100319475328460015412 100319475328460015412 No University Hospital Essen, Neurology, Essen, Germany University Hospital Essen, Neurology, Essen, Germany